Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.9750 (0.63%) ($11.9750 - $11.9750) on Thu. Feb. 25, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.01% (three month average) | RSI | 11 | Latest Price | $11.9750(0.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -22.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(58%) IWO(53%) XBI(52%) IWM(50%) IWC(48%) | Factors Impacting FOLD price | FOLD will decline at least -2.505% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.505% (StdDev 5.01%) | Hourly BBV | 0.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-24.02(-300.58%) | Inflection Point | Yes | Resistance Level | $15.98 | 5 Day Moving Average | $11.98(-0.04%) | 10 Day Moving Average | $12.65(-5.34%) | 20 Day Moving Average | $15.98(-25.06%) | To recent high | -51.9% | To recent low | 1% | Market Cap | $3.092b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |